Bryan Johnson rebranded Blueprint as Immortals Rx and added GLP-1 microdoses, NAD+, peptides, and SGLT2 inhibitors to the platform. Here's what the new stack contains and what the evidence behind each addition actually says.
Bryan Johnson's post announcing the Immortals Rx rebrand racked up hundreds of thousands of views in 48 hours. The core message: his Blueprint platform is expanding from a strict supplement and lifestyle protocol into a full compounded medication service — with microdosed GLP-1s (semaglutide, tirzepatide), direct NAD+ infusion, peptides, SGLT2 inhibitors (Jardiance, Brenzavvy), estradiol, glutathione, and hair/skin complexes now available alongside the existing Blueprint supplements.
It is easy to dismiss the announcement as product marketing. But the underlying science for several of the new additions is serious, and the move signals something important: longevity medicine is becoming a consumer category. Here is what the new stack actually contains, what the evidence says, and what you can access without a prescription.
Blueprint launched as a personal experiment: Johnson spending over $2 million per year to test whether his biological age could be reversed through ruthless optimization of sleep, diet, exercise, and supplementation. The original supplement list was relatively conventional — omega-3, creatine, NMN, vitamin D, spermidine, lycopene, astaxanthin — backed by solid human evidence.
Immortals Rx expands the model to include compounded pharmaceuticals, making prescription compounds accessible through telemedicine. The platform appears to be targeting the gap between what longevity physicians know works and what most people can actually access. The viral response suggests he identified a real demand: people who want the same interventions that physicians like Peter Attia and David Sinclair discuss, but without finding a specialist who will prescribe them.
Microdosed GLP-1s (semaglutide / tirzepatide): GLP-1 agonists were developed for type 2 diabetes, then found to produce significant weight loss, and are now being investigated for cardiovascular, renal, and potentially longevity benefits. The cardiovascular outcome trials (LEADER for semaglutide, SURPASS-CVOT for tirzepatide) show 14–20% reductions in MACE events in high-risk populations. Whether metabolically healthy individuals benefit proportionally is unknown. Microdosing specifically — much lower than weight-loss doses — is not yet validated in RCTs. Prescription required.